| Jennifer Hadley, MD, PHD | |
|
130 Inverness Plz # 312, Birmingham, AL 35242-4800 | |
| (205) 994-7016 | |
| (903) 209-2980 |
| Full Name | Jennifer Hadley |
|---|---|
| Gender | Female |
| Speciality | Psychiatry |
| Experience | 9 Years |
| Location | 130 Inverness Plz # 312, Birmingham, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447645825 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 35709 (Alabama) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Integrated Behavioral Health, Inc | 7416194113 | 75 |
News Archive
Federal officials say they will revamp strategies for dealing with bioterrorism and pandemic flu because efforts to develop medical solutions have lagged, the Los Angeles Times reports. They "announced a $1.9-billion makeover of the system for identifying and manufacturing drugs and vaccines for public health emergencies." The makeover includes plans to hasten manufacturing time and improve surveillance to detect such threats more quickly.
Emerging trends in patient care combine with advances in healthcare technology as thousands of nurses who care for high acuity and critically ill patients gather in Boston.
By the time Frederick Pegues Jr. was resting in bed at Temple University Hospital, the irony struck him hard. Here, he had just finished a month-long course in being a community health worker, sponsored by Temple University Hospital. He had learned how to help patients navigate a complicated health system. Yet he himself had not been able to get the help he needed.
Researchers at Tel Aviv University (TAU) have demonstrated that the CRISPR/Cas9 system is very effective in treating metastatic cancers, a significant step on the way to finding a cure for cancer.
OptiNose Inc. announces the filing of an Investigational New Drug (IND) with the U.S. Food and Drug Administration (FDA) in December, 2011. The FDA has completed its review and has notified OptiNose that the studies under this IND may proceed. The Company will initiate Phase III trials in adults with acute migraine with or without aura utilizing its novel intranasal technology.
› Verified 7 days ago
| Entity Name | Houston County Healthcare Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619026606 PECOS PAC ID: 9436062296 Enrollment ID: O20040219000209 |
News Archive
Federal officials say they will revamp strategies for dealing with bioterrorism and pandemic flu because efforts to develop medical solutions have lagged, the Los Angeles Times reports. They "announced a $1.9-billion makeover of the system for identifying and manufacturing drugs and vaccines for public health emergencies." The makeover includes plans to hasten manufacturing time and improve surveillance to detect such threats more quickly.
Emerging trends in patient care combine with advances in healthcare technology as thousands of nurses who care for high acuity and critically ill patients gather in Boston.
By the time Frederick Pegues Jr. was resting in bed at Temple University Hospital, the irony struck him hard. Here, he had just finished a month-long course in being a community health worker, sponsored by Temple University Hospital. He had learned how to help patients navigate a complicated health system. Yet he himself had not been able to get the help he needed.
Researchers at Tel Aviv University (TAU) have demonstrated that the CRISPR/Cas9 system is very effective in treating metastatic cancers, a significant step on the way to finding a cure for cancer.
OptiNose Inc. announces the filing of an Investigational New Drug (IND) with the U.S. Food and Drug Administration (FDA) in December, 2011. The FDA has completed its review and has notified OptiNose that the studies under this IND may proceed. The Company will initiate Phase III trials in adults with acute migraine with or without aura utilizing its novel intranasal technology.
› Verified 7 days ago
| Entity Name | Integrated Behavioral Health, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730522699 PECOS PAC ID: 7416194113 Enrollment ID: O20131007001029 |
News Archive
Federal officials say they will revamp strategies for dealing with bioterrorism and pandemic flu because efforts to develop medical solutions have lagged, the Los Angeles Times reports. They "announced a $1.9-billion makeover of the system for identifying and manufacturing drugs and vaccines for public health emergencies." The makeover includes plans to hasten manufacturing time and improve surveillance to detect such threats more quickly.
Emerging trends in patient care combine with advances in healthcare technology as thousands of nurses who care for high acuity and critically ill patients gather in Boston.
By the time Frederick Pegues Jr. was resting in bed at Temple University Hospital, the irony struck him hard. Here, he had just finished a month-long course in being a community health worker, sponsored by Temple University Hospital. He had learned how to help patients navigate a complicated health system. Yet he himself had not been able to get the help he needed.
Researchers at Tel Aviv University (TAU) have demonstrated that the CRISPR/Cas9 system is very effective in treating metastatic cancers, a significant step on the way to finding a cure for cancer.
OptiNose Inc. announces the filing of an Investigational New Drug (IND) with the U.S. Food and Drug Administration (FDA) in December, 2011. The FDA has completed its review and has notified OptiNose that the studies under this IND may proceed. The Company will initiate Phase III trials in adults with acute migraine with or without aura utilizing its novel intranasal technology.
› Verified 7 days ago
| Entity Name | Amh Enterprises Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588229843 PECOS PAC ID: 1153651666 Enrollment ID: O20190926001366 |
News Archive
Federal officials say they will revamp strategies for dealing with bioterrorism and pandemic flu because efforts to develop medical solutions have lagged, the Los Angeles Times reports. They "announced a $1.9-billion makeover of the system for identifying and manufacturing drugs and vaccines for public health emergencies." The makeover includes plans to hasten manufacturing time and improve surveillance to detect such threats more quickly.
Emerging trends in patient care combine with advances in healthcare technology as thousands of nurses who care for high acuity and critically ill patients gather in Boston.
By the time Frederick Pegues Jr. was resting in bed at Temple University Hospital, the irony struck him hard. Here, he had just finished a month-long course in being a community health worker, sponsored by Temple University Hospital. He had learned how to help patients navigate a complicated health system. Yet he himself had not been able to get the help he needed.
Researchers at Tel Aviv University (TAU) have demonstrated that the CRISPR/Cas9 system is very effective in treating metastatic cancers, a significant step on the way to finding a cure for cancer.
OptiNose Inc. announces the filing of an Investigational New Drug (IND) with the U.S. Food and Drug Administration (FDA) in December, 2011. The FDA has completed its review and has notified OptiNose that the studies under this IND may proceed. The Company will initiate Phase III trials in adults with acute migraine with or without aura utilizing its novel intranasal technology.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer Hadley, MD, PHD 130 Inverness Plz # 312, Birmingham, AL 35242-4800 Ph: (205) 994-7016 | Jennifer Hadley, MD, PHD 130 Inverness Plz # 312, Birmingham, AL 35242-4800 Ph: (205) 994-7016 |
News Archive
Federal officials say they will revamp strategies for dealing with bioterrorism and pandemic flu because efforts to develop medical solutions have lagged, the Los Angeles Times reports. They "announced a $1.9-billion makeover of the system for identifying and manufacturing drugs and vaccines for public health emergencies." The makeover includes plans to hasten manufacturing time and improve surveillance to detect such threats more quickly.
Emerging trends in patient care combine with advances in healthcare technology as thousands of nurses who care for high acuity and critically ill patients gather in Boston.
By the time Frederick Pegues Jr. was resting in bed at Temple University Hospital, the irony struck him hard. Here, he had just finished a month-long course in being a community health worker, sponsored by Temple University Hospital. He had learned how to help patients navigate a complicated health system. Yet he himself had not been able to get the help he needed.
Researchers at Tel Aviv University (TAU) have demonstrated that the CRISPR/Cas9 system is very effective in treating metastatic cancers, a significant step on the way to finding a cure for cancer.
OptiNose Inc. announces the filing of an Investigational New Drug (IND) with the U.S. Food and Drug Administration (FDA) in December, 2011. The FDA has completed its review and has notified OptiNose that the studies under this IND may proceed. The Company will initiate Phase III trials in adults with acute migraine with or without aura utilizing its novel intranasal technology.
› Verified 7 days ago
Rayford W Thweatt, Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 619 19th Street South, Birmingham, AL 35233 Phone: 205-934-6600 | |
Marla B Morgan, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 619 19th Street South, Birmingham, AL 35233 Phone: 205-934-6600 | |
Robins J Newton, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2700 10th Ave S Ste 400, Birmingham, AL 35205 Phone: 205-918-0507 Fax: 205-930-2716 | |
Mohamed Kazamel, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1717 6th Ave S, Birmingham, AL 35233 Phone: 800-822-8816 | |
Dr. Rodney K Swillie, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3686 Grandview Pkwy Ste 600, Birmingham, AL 35243 Phone: 205-971-3600 Fax: 844-772-0468 | |
Sandra L Frazier, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 619 19t Street South, Birmingham, AL 35233 Phone: 205-934-6600 | |
Michael Alonzo Lopez, M.D., PH.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1600 6th Ave S # Chb314, Birmingham, AL 35233 Phone: 205-996-7850 |